3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Ovarian Neoplasms
9
Fallopian Tube Neoplasms
8
Breast Neoplasms
6
Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Recurrence
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Small Cell Lung Carcinoma
2
Metastatic Castration Resistant Prostate Cancer
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Prostate Cancer Metastatic
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Lung Neoplasms
1
Genital Neoplasms, Male
1
Genital Neoplasms, Female
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Advanced Gastric Cancer
1
Adenocarcinoma, Clear Cell
1
Adenocarcinoma of Lung
1
Interventions
senaparib
7
pembrolizumab
7
Irinotecan
6
Paclitaxel
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Nivolumab
4
Fluorouracil
4
Bevacizumab
4
Rifampin
3
Midazolam
3
Leucovorin
3
Itraconazole
3
Injections
3
pertuzumab
2
ontuxizumab
2
navoximod
2
atezolizumab
2
Gemcitabine
2
vofatamab
1
tremelimumab
1
trastuzumab duocarmazine
1
talazoparib
1
sotorasib
1
sintilimab
1
saracatinib
1
rucaparib
1
ridaforolimus
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumor
×
rucaparib
×
Clear all
NCT02986100
2023-06-09
AME
pharmaand GmbH
Phase 1
Completed
6 enrolled